Bristol-Myers Squibb Co. [NYSE: BMY] stock went on an upward path that rose over 1.58% on Friday, amounting to a one-week price increase of more than 3.04%.
Over the last 12 months, BMY stock dropped by -12.06%. The one-year Bristol-Myers Squibb Co. stock forecast points to a potential upside of 2.0. The average equity rating for BMY stock is currently 2.89, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $103.21 billion, with 2.03 billion shares outstanding and 2.03 billion shares in the current float. Compared to the average trading volume of 13.65M shares, BMY stock reached a trading volume of 22230655 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Bristol-Myers Squibb Co. [BMY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $51.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.89. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Bristol-Myers Squibb Co. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on July 29, 2024. The new note on the price target was released on March 11, 2024, representing the official price target for Bristol-Myers Squibb Co. stock. Previously, the target price had yet another drop from $77 to $54, while Redburn Atlantic kept a Neutral rating on BMY stock. On January 03, 2024, analysts decreased their price target for BMY shares from 68 to 60.
The Average True Range (ATR) for Bristol-Myers Squibb Co. is set at 1.25, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 2.22. The Price to Book ratio for the last quarter was 6.06, with the Price to Cash per share for the same quarter was set at 3.28. Price to Free Cash Flow for BMY in the course of the last twelve months was 7.97 with Quick ratio for the last quarter at 1.02.
BMY Stock Performance Analysis:
Bristol-Myers Squibb Co. [BMY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.04. With this latest performance, BMY shares gained by 3.77% in over the last four-week period, additionally sinking by -6.12% over the last 6 months – not to mention a drop of -12.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 60.51, with the RSI for the last a single of trading hit 62.33, and the three-weeks RSI is set at 59.67 for Bristol-Myers Squibb Co. [BMY]. The present Moving Average for the last 50 days of trading for this stock 48.38, while it was recorded at 50.39 for the last single week of trading, and 47.72 for the last 200 days.
Insight into Bristol-Myers Squibb Co. Fundamentals:
Bristol-Myers Squibb Co.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.02 and a Current Ratio set at 1.16.
BMY Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Co. go to -4.81%.
Bristol-Myers Squibb Co. [BMY] Institutonal Ownership Details
There are presently around $78.03%, or 78.11%% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 186.57 million shares, which is approximately 9.2225%. BLACKROCK INC., holding 158.66 million shares of the stock with an approximate value of $$6.59 billion in BMY stocks shares; and BLACKROCK INC., currently with $$3.8 billion in BMY stock with ownership which is approximately 4.5203%.
